Vascular complications in living donor liver transplantation at a high‐volume center: Evolving protocols and trends observed over 10 years

Shiraz Ahmad Rather, Mohammed A. Nayeem, Shaleen Agarwal, Neerav Goyal, Subash Gupta – 23 November 2016 – Vascular complications continue to have a devastating effect on liver transplantation recipients, even though their nature, incidence, and outcome might have actually changed with increasing experience and proficiency in high‐volume centers. The aim of this study was to analyze the trends observed in vascular complications with changing protocols in adult and pediatric living donor liver transplantation over 10 years in 2 time frames in terms of nature, incidence, and outcome.

Low‐Dose Lipopolysaccharide Causes Biliary Injury by Blood Biliary Barrier Impairment in a Rat Hepatic Ischemia/Reperfusion Model

Janske Reiling, Kim R. Bridle, Marion Gijbels, Frank G. Schaap, Lesley Jaskowski, Nishreen Santrampurwala, Laurence J. Britton, Catherine M. Campbell, Steven W. M. Olde Damink, Darrell H. G. Crawford, Cornelius H. C. Dejong, Jonathan Fawcett – 23 November 2016 – This study explored whether bacterial endotoxins, in the form of lipopolysaccharides (LPS), could have an injurious effect on the biliary tract in conjunction with ischemia.

Bariatric surgery for nonalcoholic steatohepatitis: A clinical and cost‐effectiveness analysis

Matthew J. Klebanoff, Kathleen E. Corey, Jagpreet Chhatwal, Lee M. Kaplan, Raymond T. Chung, Chin Hur – 23 November 2016 – Nonalcoholic steatohepatitis (NASH) affects 2%‐3% of the US population and is expected to become the leading indication for liver transplantation in the next decade. Bariatric surgery may be an effective but expensive treatment for NASH. Using a state‐transition model, our analysis assessed the effectiveness and cost‐effectiveness of surgery to manage NASH.

A novel glucagon‐like peptide 1/glucagon receptor dual agonist improves steatohepatitis and liver regeneration in mice

M. Pilar Valdecantos, Virginia Pardo, Laura Ruiz, Luis Castro‐Sánchez, Borja Lanzón, Elisa Fernández‐Millán, Carmelo García‐Monzón, Ana I. Arroba, Águeda González‐Rodríguez, Fernando Escrivá, Carmen Álvarez, Francisco J. Rupérez, Coral Barbas, Anish Konkar, Jacqui Naylor, David Hornigold, Ana Dos Santos, Maria Bednarek, Joseph Grimsby, Cristina M. Rondinone, Ángela M.

Immunosuppression in pediatric liver transplant recipients: Unique aspects

Tamir Miloh, Andrea Barton, Justin Wheeler, Yen Pham, Winston Hewitt, Tara Keegan, Christine Sanchez, Pinar Bulut, John Goss – 22 November 2016 – Pediatric liver transplantation has experienced improved outcomes over the last 50 years. This can be attributed in part to establishing optimal use of immunosuppressive agents to achieve a balance between minimizing the risks of allograft rejection and infection. The management of immunosuppression in children is generally more complex and can be challenging when compared with the use of these agents in adult liver transplant patients.

Management of renal failure in end‐stage liver disease: A critical appraisal

Xingxing S. Cheng, Jane C. Tan, W. Ray Kim – 22 November 2016 – Renal failure is a late consequence of end‐stage liver disease (ESLD). Even with liver transplantation, pretransplant renal impairment remains a strong predictor of posttransplant mortality. This review seeks to summarize and critically appraise common therapies used in this setting, including pharmacologic agents, procedures (transjugular intrahepatic portosystemic shunt, renal replacement therapy), and simultaneous liver‐kidney transplantation.

Evaluation of coronary artery disease in potential liver transplant recipients

Brian J. Hogan, Enoka Gonsalkorala, Michael A. Heneghan – 22 November 2016 – Improvements in the management of patients undergoing liver transplantation (LT) have resulted in a significant increase in survival in recent years. Cardiac disease is now the leading cause of early mortality, and the stress of major surgery, hemodynamic shifts, and the possibilities of hemorrhage or reperfusion syndrome require the recipient to have good baseline cardiac function.

Subscribe to